Phyllodes tumours constitute an uncommon but complex group of mammary fibroepithelial lesions. Accurate and reproducible grading of these tumours has long been challenging, owing to the need to assess multiple stratified histological parameters, which may be weighted differently by individual pathologists. Distinction of benign phyllodes tumours from cellular fibroadenomas is fraught with difficulty, due to overlapping microscopic features. Similarly, separation of the malignant phyllodes tumour from spindle cell metaplastic carcinoma and primary breast sarcoma can be problematic. Phyllodes tumours are treated by surgical excision. However, there is no consensus on the definition of an appropriate surgical margin to ensure completeness of excision and reduction of recurrence risk. Interpretive subjectivity, overlapping histological diagnostic criteria, suboptimal correlation between histological classification and clinical behaviour and the lack of robust molecular predictors of outcome make further investigation of the pathogenesis of these fascinating tumours a matter of active research. This review consolidates the current understanding of their pathobiology and clinical behaviour, and includes proposals for a rational approach to the classification and management of phyllodes tumours.
Introduction
Phyllodes tumours of the breast constitute an uncommon but fascinating group of fibroepithelial neoplasms that have a morphological resemblance to the intracanalicular fibroadenoma at the benign end of the spectrum, but with increased stromal cellularity and leaf-like architecture. Phyllodes tumours are classified into benign, borderline and malignant grade categories on the basis of a constellation of histological parameters, i.e. the degree of stromal cellularity and atypia, mitotic count, stromal overgrowth, and the nature of their tumour borders. 1 As each microscopic parameter has two to three tiers of stratification, there are significant challenges in accurate and reproducible categorization.
carcinoma. The distinction between benign phyllodes tumour and cellular fibroadenoma is especially problematic on core biopsies. Currently, cellular fibroepithelial lesions diagnosed on core biopsy may be subjected to complete removal through either vacuum-assisted or open excision. Surgical excision is usually the preferred procedure, as it allows negative margins to be obtained in the event that the final diagnosis is a phyllodes tumour. What constitutes a sufficient margin for phyllodes tumours is yet another unresolved dilemma.
Debate regarding the relationship between fibroadenoma, a common benign neoplasm, and phyllodes tumour, a rare tumour with uncertain behaviour, continues. Fibroadenoma-like areas are not infrequently encountered in phyllodes tumours, although the frequency of such an observation is not known.
In this review, we provide a collective stance on these issues that can serve as a practical guide for pathological reporting and understanding of phyllodes tumours.
Grading of phyllodes tumours
The criteria for diagnosis and grading of phyllodes tumours are summarized in the recommendations of the World Health Organization (WHO) classification of tumours of the breast. 1 Briefly, phyllodes tumours are diagnosed when the fibroepithelial architecture shows an exaggerated intracanalicular pattern with leaf-like fronds protruding into cystically dilated spaces accompanied by stromal hypercellularity. A benign phyllodes tumour shows mildly increased stromal cellularity as compared with a fibroadenoma, and has minimal nuclear atypia, pushing borders, and mitoses of ≤4/10 high-power fields (HPFs). Stromal overgrowth (defined as the presence of stroma without epithelium in at least one low-power field as observed with a × 4 microscope objective) is not present. The key feature distinguishing a benign phyllodes tumour from a fibroadenoma with an exaggerated intracanalicular growth pattern is the presence of increased stromal cellularity. In the absence of well-developed stromal fronds, the presence of elongated, branching and cleftlike ducts meandering through the cellular stroma, giving a staghorn appearance, may be a histological clue to the diagnosis of a phyllodes tumour.
At the other end of the spectrum, a malignant phyllodes tumour shows marked stromal cellularity and atypia, has permeative margins, and has mitotic activity of at least 10/10 HPFs. Stromal overgrowth is usually easily identified. Phyllodes tumours with intermediate features are assigned to the borderline category. Previous grading schemes have assessed similar histological parameters, including that described by Azzopardi in 1979 , which incorporated the nature of the tumour edge, stromal overgrowth, mitotic activity, and cellular atypia. 2 It is important to acknowledge that there are no objective criteria for separating minimal/ mild from moderate and marked degrees of stromal hypercellularity and atypia, and this may confound grading attempts. A practical guide for assessing stromal cellularity is to centre on the most cellular zones of the lesion, with mild hypercellularity characterized by a slight increase in stromal cells as compared with normal perilobular stroma, with evenly spaced nuclei that are not touching or overlapping. Marked stromal cellularity shows confluent areas of densely overlapping nuclei, whereas moderate stromal cellularity has findings that are intermediate, with some overlapping stromal nuclei (Figure 1 ). Mild stromal atypia shows nuclei with little variation in size, with smooth nuclear contours. Moderate atypia shows some variation in nuclear size, with wrinkled nuclear membranes, to an extent exceeding that in mild atypia but less than that in marked atypia. Marked atypia shows marked variation in nuclear size, coarse chromatin, and irregular nuclear membranes with discernible nucleoli (Figure 2 ). 3 The perceived clinical relevance of grading phyllodes tumours is to predict clinical behaviour: benign tumours have the potential to locally recur; borderline tumours have the potential to recur locally, and have a very low risk of metastasis; and malignant tumours have the highest risk of metastatic behaviour, which may eventually prove fatal. However, it is accepted that adverse events are, in general, rare for all forms of phyllodes tumours when they are subjected to complete local excision.
Although the guidelines may appear straightforward, their application can be fraught with ambiguity. Furthermore, how the subdivisions for each microscopic parameter interact to constitute the final grade is subjective. It is also not uncommon for phyllodes tumours to show intratumoral heterogeneity, and harbour features that typify benign lesions in some areas, and characteristics of borderline and malignant lesions in other foci. For instance, a phyllodes tumour with marked stromal atypia and brisk mitotic activity, but without permeative margins or stromal overgrowth, may be considered by some pathologists to be borderline, whereas others may regard the tumour as malignant, owing to different weighting of the relevance of each feature, with prioritization of stromal atypia ( Figure 3) . A practical approach is to grade a phyllodes tumour as malignant when it shows all of the histological changes of malignancy, and as borderline when not all malignant characteristics are present. The presence of a malignant heterologous element such as liposarcoma, chondrosarcoma or osteosarcoma relegates the tumour into the malignant category regardless of whether other histological parameters (stromal hypercellularity, atypia, mitotic rate, overgrowth, and nature of tumour borders) show changes characteristic of malignant phyllodes tumours. In an effort to comprehend which microscopic parameters are more influential in determining the clinical behaviour of phyllodes tumours, a study of 605 cases concluded that stromal atypia, mitoses, overgrowth and surgical margins (AMOS criteria) 4 were of independent significance in predicting behaviour, with surgical margin status being the most important. A nomogram was developed by the use of a mathematical formula that could be applied to counsel patients about their individual risk for recurrence. 4 borderline and malignant tumours, respectively, 1 with distant metastases being encountered in 9% of patients with malignant tumours. Overall, recurrence rates in the literature are 10-17%, 14-25% and 23-30% for benign, borderline and malignant phyllodes tumours, respectively. 1 Interestingly, in a clinicopathological analysis by Karim et al., there was a suggestion that Asian patients experienced a higher recurrence rate than those of non-Asian ethnicity. 14 Grade progression during local recurrence of phyllodes tumours can occur. There have been several suggestions regarding why this happens, including a lack of representative sampling of the initial tumour, tumour heterogeneity with the presence of stromal subclones, 15 and loss of stromal-epithelial interdependency. 16 In a study of 335 phyllodes tumours, it was noted that metastases and death from phyllodes tumours were consistently preceded by a primary malignant diagnosis, 17 suggesting that a key aim should be to recognize the malignant category, in order for effective therapy to be given at the outset. Metastases in phyllodes tumours invariably indicate a dismal prognosis, with ensuing death. 4, 18 Distant metastases occur mostly to the lung and skeleton, but almost all organ sites have been affected (Figure 4 ). Histologically, metastases comprise malignant stromal elements without accompanying epithelium. 17, 19, 20 Two exceptional cases of metastatic phyllodes tumours harbouring an epithelial component have been described as case reports. One represented inclusion of lung alveolar tissue within the metastatic tumour stroma, as confirmed by immunoreactivity of the epithelial component for antisurfactant apoproteins. 21 The other case showed floridly hyperplastic, adenosis-like epithelium, rimmed by actin and calponin-positive myoepithelial cells, within both the primary and metastatic tumours, which showed liposarcomatous differentiation. 22 The metastatic epithelial component duplicated the immunoreactivity for oestrogen receptor (ER), progesterone receptor and gross cystic disease fluid protein 15 seen in the epithelium of the primary tumour.
How often do phyllodes tumours metastasize, and do benign tumours ever do so? Table 1 shows metastatic rates according to phyllodes tumour grades that have been described by various authors. 4, [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] The singular documentations of metastatic disease following a diagnosis of benign phyllodes tumour were by Abdalla et al. and Chaney et al., where distant metastases were reported to occur in 3.2%, 11.1% and 28.6% of benign (1/31), borderline (3/27) and malignant (6/21) tumours, 26 and in 1.7%, 0% and 26.7% of benign (1/59), borderline (0/12) and malignant (8/30) tumours, 23 respectively. However, pathological details of these unusual cases of metastatic benign phyllodes tumour were not provided.
It may be reasonably inferred that metastatic disease is a vanishingly rare occurrence in benign phyllodes tumours, with the qualification that all tumours should be adequately sampled to account for intratumoral heterogeneity. Conversely, metastatic behaviour is an established risk for malignant phyllodes tumours, albeit still uncommon, and pathological diagnosis should focus on accurately identifying this group of tumours.
Relationship between fibroadenoma and phyllodes tumour
Phyllodes tumours are generally regarded as de-novo lesions derived from periductal and specialized lobular stroma. The initiation of tumorigenesis may hinge on epithelial-stromal interactions. However, the histological overlap between fibroadenoma and phyllodes tumour has long raised the question of pathogenetic kinship. Table 2 shows the studies that have explored this relationship and their salient findings. [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] Interestingly, a mother and daughter pair with benign phyllodes tumours was also described, raising the possibility of hereditary linkage, 43 and a TP53 founder mutation was discovered in phyllodes tumours from Brazil. 51 A study from France discovered chromosome imbalances in 55%, 91% and 100% of benign, borderline and malignant phyllodes tumours, respectively, with 1q gains being associated with borderline and malignant grades. It was suggested that phyllodes tumours could be divided into two genetically distinct classes, with benign tumours in one group and borderline/malignant phyllodes in the other. 52 More recently, highly recurrent mediator complex subunit 12 (MED12) somatic mutations in exon 2 were discovered in 59% of 98 fibroadenomas studied, 44 with most mutations occurring in codon 44. The same mutation in MED12 is a common genetic anomaly in uterine smooth muscle tumours. 53, 54 Laser capture microdissection established that MED12 mutations were present in stromal but not in epithelial cells of fibroadenomas. A subsequent study by Ng et al. found that MED12 mutations were also prevalent in phyllodes tumours, with 65.1% of benign, 65.6% of borderline and 42.8% of malignant phyllodes tumours, respectively, showing mutations. 50 The overall rate of MED12 mutations was strikingly similar in phyllodes tumours (62.5%) and fibroadenomas (59%), with a comparable rate of mutations in codon 44 of MED12 supporting a close molecular relationship. 44, 50 Other studies have confirmed the high prevalence of MED12 mutations in fibroadenomas and phyllodes tumours. [45] [46] [47] [48] [49] Using targeted next-generation sequencing, Cani et al. found that malignant phyllodes tumours harboured additional genetic aberrations in tumour suppressor genes, consistent with their aggressive biological behaviour. 45 Of particular prognostic import is the finding by Ng et al. that tumours with MED12 mutations were significantly associated with longer disease-free survival, possibly related to hormonal dependence. 50 Although evidence for the direct evolution of phyllodes tumours from fibroadenomas remains limited, with very recent confirmation of linear progression in some cases, 55 it is clear that these fibroepithelial lesions possess molecular similarities, in addition to their striking morphological resemblance in some cases.
Distinguishing cellular fibroadenoma from benign phyllodes tumour
In a study of 21 cellular fibroepithelial lesions evaluated by 10 specialist breast pathologists using the WHO criteria, only for two cases was uniform agreement achieved with regard to whether the lesion represented a cellular fibroadenoma or phyllodes tumour. It is noted, however, that these cases were highly selected from a consultation series, and problematic lesions were therefore over-represented. 56 When cellular fibroadenomas and benign phyllodes tumours were combined and compared with borderline and malignant phyllodes tumours as another group, the level of agreement improved considerably, with complete concordance in 53% of cases. These findings testify to the challenges of separating cellular fibroadenomas from benign phyllodes at one end of the spectrum, and also highlight the difficulty of achieving consensus in grading phyllodes tumours ( Figure 5 ). It is important to note that fibroadenomas in the paediatric age group tend to have increased stromal cellularity, which should not be overinterpreted. 57 Of 68 paediatric breast fibroepithelial lesions analysed in a recent study, 16 cases showed mitotic activity. These included 15 fibroadenomas of simple, cellular and juvenile types, 11 of which showed 1-2 mitoses/10 HPF, and the remaining five fibroepithelial lesions showed mitotic activity ranging from 3 to 5/10 HPF. 57 In another study, by Ross et al., of breast fibroepithelial tumours in adolescent females aged up to 18 years, the mean stromal mitotic counts/10 HPF for 11 benign phyllodes tumours, five 'usual' fibroadenomas, 12 juvenile fibroadenomas and three 'variant' juvenile fibroadenomas (with pericanalicular stromal expansion) were 3 (range: 1-7), 1 (range: 0-2), 2 (range: 0-4) and 3 (range: 0-7), respectively. 58 Faiz et al. also found stromal mitoses in all fibroadenoma subtypes (cellular, classic, and juvenile) among 119 paediatric cases with up to 5 mitoses/10 HPF being observed in two cases. 59 Therefore, apart from potentially increased stromal cellularity in paediatric fibroepithelial tumours, mitotic activity may also be encountered, up to 7 mitoses/10 HPF. [57] [58] [59] A cautious and measured approach is therefore needed when cellular and mitotically active paediatric fibroepithelial lesions are evaluated. A diagnosis of phyllodes tumour should be based on the finding of well-developed stromal fronds accompanied by increased stromal hypercellularity.
Numerous studies have attempted to analyse the histology of phyllodes tumours. [60] [61] [62] [63] [64] A study by Choi et al. found a concordance rate of only 60% between core needle biopsies and excision specimens, with larger tumour size being significantly correlated with discordant biopsy results. 65 Assessment of clinicoradiological tumour attributes such as size and radiographic density may contribute to clinical decision-making. 66, 67 Notwithstanding that, histomorphological assessment of the excised lesion remains the practical gold standard in diagnosis and grading, 60, 68 with the presence of leafy architecture and increased stromal cellularity typically being used as the discriminants between cellular fibroadenoma and benign phyllodes tumour. Fibroadenomas that contain stromal multinucleated giant cells can also be mistaken for phyllodes tumours, 69 and there may be a potential role for Ki67 proliferation activity as an adjunctive aid. 3 The question of whether there is always a need to precisely delineate a benign phyllodes tumour from a cellular fibroadenoma arises. The answer is important, as many surgeons would perform a second surgical procedure to achieve negative margins for a benign phyllodes tumour initially enucleated without margin clearance. The WHO Working Group has proposed that the term 'benign fibroepithelial neoplasm' be employed in equivocal cases, 70 in order to avoid overtreatment. This term, however, should be used sparingly, as it does not represent a new diagnostic category.
There has been both direct and indirect evidence that benign phyllodes tumours may be treated less aggressively. In a study of 37 women with locally recurrent phyllodes tumours, it was concluded that an expectant approach may be acceptable for initially diagnosed benign and borderline tumours, with complete resection being achieved during any subsequent recurrent episode. 27 Although most surgeons would be uncomfortable with not re-excising a borderline phyllodes tumour with positive margins, it would be reasonable to assume a 'watchful waiting' strategy for benign lesions. The rate of recurrence for fibroadenomas after ultrasound-guided vacuum assisted percutaneous excision is listed as 15%, 71 whereas Organ et al. described a recurrence rate of 17% for surgically excised fibroadenomas. 72 However, as acknowledged by the authors, determining whether the recurrence was a 'true recurrence' of the same tumour or another primary tumour was difficult, if not impossible, owing to the retrospective nature of the study, particularly if the same breast was involved. In a previous article, also by Organ, 73 it was stated that 'recurrences' of fibroadenomas were undoubtedly serial presentations of multicentric lesions. This contrasts with a 10.9% recurrence rate of benign phyllodes tumours in one series, 4 occurring typically at the site of previous surgery. A very low recurrence rate of 3.4% was reported in benign phyllodes tumours in a study by Korean investigators, with all recurrent cases remaining benign, 74 without any association with surgical margin status. Teo et al., in a retrospective review of 44 Asian cases, found no cases of local recurrence in benign tumours treated with simple excision (enucleation), regardless of margin status, after a mean follow-up of 47.6 months. 75 Hence, a benign phyllodes tumour diagnosed after representative sampling of an excision specimen may be conservatively handled even when positive margins are encountered.
Conversely, malignant phyllodes tumours are associated with a recurrence rate of 29.6% 4 , with metastases and death being observed in 22%, 1 underscoring the need to recognize this subset of aggressive phyllodes tumours for complete surgical eradication.
Distinguishing malignant phyllodes tumour from primary breast sarcoma and spindle cell metaplastic breast carcinoma
At the other end of the histological spectrum, a high-grade spindle cell neoplasm of the breast invokes different diagnostic considerations, namely malignant phyllodes tumour with sarcomatous overgrowth, spindle cell metaplastic breast carcinoma, and primary or secondary breast sarcoma.
The architectural hallmark of leaf-like fronds surmounted by benign glandular epithelium serves to delineate phyllodes tumour from its mimics. In some malignant phyllodes tumours, however, the stromal overgrowth may be so prominent that epithelial elements can be difficult to find, requiring extensive sampling with many sections for their identification. The stroma of a malignant phyllodes tumour may, on occasion, show heterologous sarcomatous differentiation, most frequently liposarcoma, but also including myosarcoma, angiosarcoma, chondrosarcoma, and osteosarcoma ( Figure 6 ). A spindle cell metaplastic breast carcinoma contains varying proportions of a malignant epithelial component, which may be of squamous, glandular or adenosquamous type. Metaplastic carcinomas can also be entirely devoid of frank epithelial elements, or additionally show heterologous mesenchymal differentiation, although liposarcomatous elements are hardly ever seen. The presence of ductal carcinoma in situ adjacent to a malignant mammary spindle cell tumour greatly favours a diagnosis of metaplastic carcinoma. Primary breast sarcomas, which are distinctly uncommon, 76 and sarcomas metastatic to the breast, which are exceptionally rare, have no distinguishing histological features of either phyllodes tumour or metaplastic breast carcinoma, and can have histological attributes common to sarcomas at any site. A history of previous or metastatic sarcoma, imaging and clinical correlation may be helpful. Table 3 summarises the features of these three entities.
On limited samples such as needle core biopsies, accurate diagnosis of high-grade malignant mammary spindle cell lesions can prove exceedingly challenging, especially when an epithelial element is elusive. The demonstration of diffuse cytokeratin or p63 immunoreactivity in the malignant spindle cells supports a diagnosis of metaplastic carcinoma, 77, 78 although interpretation must be tempered in cases of focal keratin or p63 expression, as such reactivities have been described in stromal cells of phyllodes tumours. 79, 80 The utility of p40 in a similar diagnostic setting remains under investigation; so far, it has been found to be more specific but less sensitive than p63. [80] [81] [82] However, like p63, p40 may stain stromal cells of phyllodes tumours in some cases. CD34 reactivity, which is well described in the stromal cells of phyllodes tumours, has been reported to be inversely related to adverse histological features; 6, 8, 13, [83] [84] [85] [86] this assumes importance if CD34 were to be considered for diagnostic utility in differentiating high-grade spindle cell lesions of the breast, as malignant phyllodes tumours are less likely to express CD34. Other markers, including bcl-2 86, 87 which is more frequently expressed in phyllodes tumours, CD117, 83, 88, 89 which shows increased expression in higher-grade phyllodes tumours, and sarcoma-specific molecular cytogenetic alterations are possible diagnostic adjuncts. Although routinely employed in the diagnosis of fibromatosis that may occur in the breast, aberrant nuclear expression of β-catenin has been reported in the stroma of phyllodes tumours, as well as in metaplastic carcinomas. [90] [91] [92] [93] [94] The use of β-catenin as a solitary marker in the assessment of mammary spindle cell lesions must be cautioned against.
Adequate sampling, entailing at least one section per centimetre of maximal tumour size, with additional sampling of grossly heterogeneous areas and meticulous morphological assessment, remains the keystone of diagnosis, buttressed by clinical, radiological and immunohistochemical correlation.
Epithelial-stromal interactions in phyllodes tumours
In 1992, Sawhney et al. observed that stromal mitotic activity tended to occur close to the epithelial compartment in fibroepithelial lesions, and hypothesized that stromal growth in these tumours depended, in part, on the epithelial component. It was suggested that increasing malignancy correlated with loss of stromal dependency on the epithelium. 95 Since then, there have been a number of studies supporting this view. Sawyer et al. demonstrated allelic imbalances in chromosomes 3p and 1q in both epithelial and stromal elements of phyllodes tumours. 96 These authors also noted that stromal proliferation in benign phyllodes tumours was dependent on abnormalities in the Wnt pathway consequent to Wnt5a expression in the epithelial component, with malignant progression being linked to independence from the latter. 91 E-cadherin is a known epithelial differentiation marker that is affected by the Wnt signalling pathway, and its expression in the epithelium of phyllodes tumours was correlated with recurrence and shorter tumour-specific survival. 97 Feakins et al.
found epithelial platelet-derived growth factor (PDGF)/stromal PDGF receptor-β copositivity that correlated with disease-related death in 43% of phyllodes tumours. 98 Clonal abnormalities have been detected in both epithelial and stromal components of phyllodes tumours in studies by Dietrich et al. 99 and Kuijper et al. 39 Additional work on biomarker expression in epithelial and stromal elements of phyllodes tumours lends further credence to their interactions. 16, 97, [100] [101] [102] For example, the level of CXCR4, an epithelial-stromal interaction-related molecule, was found to be increased in the stromal component of highergrade phyllodes tumours. 10 Table 4 summarizes findings from studies that have evaluated the expression of hormone receptors in phyllodes tumours, [103] [104] [105] [106] [107] [108] [109] with one report documenting HER2/c-erbB2 reactivity as well. 106 ERα expression was confined to the epithelial compartment, without any stromal positivity, with one study demonstrating an inverse correlation with grade. 106 ERβ expression, on the other hand, has been observed in stromal cells of phyllodes tumours. 108, 109 The practical significance of these observations is unclear. Although the current data indicate a limited role for hormones in phyllodes tumours, the recently discovered MED12 mutations in these tumours may lead to a resurgence of interest, as the MED12 abnormality is linked to aberrantly activated oestrogen signalling. 44, 50 
Hormone receptors

Surgical margins
The mainstay of phyllodes tumour management has traditionally consisted of surgical excision with wide tumour-free margins, generally defined by some authors as at least 10 mm. 31 However, more recent data suggest that not all phyllodes tumours require excision with such wide margins. 32, 110, 111 In cases of large tumours, this may render breast conservation impracticable. 112, 113 Table 5 summarizes pertinent findings from studies that have addressed surgical margins in phyllodes tumours. [23] [24] [25] 28, 32, 110, 111, [114] [115] [116] [117] [118] [119] [120] Drawing a parallel from an opinion advanced by Wood regarding the issue of surgical margins in invasive breast cancer, there appears to be a dearth of data supporting a precise width of tumour-free tissue that is significantly associated with reduced tumour recurrence. 121 Although an increasing amount of normal tissue confers greater confidence in the adequacy of excision (with ensuing diminishing cosmetic results), a single layer of cells between the tumour and the surgical plane constitutes, in theory, a clear margin. 121 This does not take into account myriad factors that may undermine the accuracy of representation in any slide, including tumour irregularity, multifocality, ink seepage, sampling and technical sectioning issues, among others. Onkendi et al., in a study of 67 borderline and malignant phyllodes tumours from the Mayo Clinic, found that the extent of surgical excision had no impact on disease-free survival. 110 An analysis of 164 cases by Jang et al. revealed no significant local control advantage conferred by wide (at least 10 mm) margins over narrower margins. 32 Lin et al., in a single-institution series of 33 cases, found no relationship between width of surgical margin and disease recurrence. 111 Tan et al. Page 10 Histopathology. Author manuscript; available in PMC 2016 September 19.
Notwithstanding the above, many institutions elect to offer additional surgical treatment for close margins. Mangi et al., in a study of 40 cases from the Massachusetts General Hospital, found that post-excision recurrences were confined to cases with positive margins, or margins of <10 mm. Following re-excision with a 10-mm clearance, patients remained recurrence-free. 117 Yom et al., in a recent Korean study of 285 cases, investigated the benefit of a second excision following initial 'inadequate' (<10 mm) clearance. Tumour size and mitotic activity were found to be independently prognostic of local recurrence, whereas margin status and surgical procedure were not. On the basis of these findings, the group proposed that wide margins, if necessary via re-excision, should be the goal in treating small (<50 mm) tumours with high mitotic activity (>10 mitoses/10 HPFs), as these tumours constituted a distinct group associated with a significant (55.6%) local recurrence rate. 120 As convincing evidence for an appropriate margin width in surgically excised phyllodes tumours remains elusive, it may be pragmatic to consider tumour on ink, or <1 mm, as a positive margin. A conservative approach can be accorded to benign phyllodes tumours that have been initially enucleated without margins. 27, 74, 75 Excision with negative margins should be achieved for recurrent and malignant phyllodes tumours.
Because of the infrequency of nodal disease in phyllodes tumours, most investigators do not recommend routine axillary dissection. 29, 115, 117, [122] [123] [124] 
Adjuvant therapy
Adjuvant radiation therapy has been offered to patients with malignant phyllodes tumours on an individualized basis, although its precise role is controversial. 23, 118, [125] [126] [127] [128] An analysis of 3120 malignant cases from the US National Cancer Data Base by Gnerlich et al. showed a pronounced increase in the use of radiotherapy (9.5% in 1998-1999 versus 19.5% in 2008-2009), which, although being associated with reduced local recurrence, had no impact on disease-free or overall survival. 129 In a study of malignant phyllodes tumours by Mitus et al.,
conservatively treated cases were subjected to radiation if tumour-free margins were <10 mm, whereas no adjuvant therapy was administered if margins were wide (≥10 mm). The two conservatively treated groups showed identical 5-year disease-free survival rates. 119 Belkacémi et al., in an analysis of cases collected from the Rare Cancer Network between 1971 and 2003, found that adjuvant radiotherapy for borderline and malignant tumours yielded superior 10-year local control rates (86% with radiation versus 59% without radiation), but no survival benefit. 29 There are no randomized clinical trials assessing the role of adjuvant chemotherapy in malignant phyllodes tumours. The merits of systemic therapy are therefore considered on a case-by-case basis.
Summary and practical recommendations
Phyllodes tumours present distinct challenges relating to their diagnosis, classification, predicted behaviour, and clinical management. On the basis of the currently available knowledge, a few practical recommendations may be useful:
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1.
Grading of phyllodes tumours should aim to achieve accuracy and consistency at the benign and malignant ends of the spectrum.
2.
Definitive distinction between cellular fibroadenomas and benign phyllodes tumours may not be crucial, in light of similar reported recurrence rates. The term benign fibroepithelial lesion/neoplasm may be recommended for cases where clear diagnostic distinction cannot be made, although this should be used sparingly.
3.
Malignant phyllodes tumours are diagnosed when there are marked stromal hypercellularity, atypia, increased mitoses of ≥10/10 HPFs, permeative tumour borders, and stromal overgrowth. The presence of a malignant heterologous component places the tumour into the malignant category regardless of other histological features.
4.
A conservative approach can be accorded to benign phyllodes tumours that have been initially enucleated without margins.
5.
Excision with negative margins should be achieved for recurrent and malignant phyllodes tumours. Most would recommend that borderline tumours should also be completely excised. Although the literature often refers to a margin width of at least 10 mm, a robust evidence base to support this approach is lacking. Therefore, an ideal margin width remains to be determined, and may need to be considered in relation to factors such as tumour size and cosmesis.
6.
From a diagnostic and management perspective, it is important to accurately recognize malignant phyllodes tumours, which should be surgically eradicated and effectively treated at diagnosis, as these tumours have a well-established but relatively infrequent risk of metastasis and death.
7.
The role of adjuvant radiation therapy in borderline and malignant tumours remains to be defined. Routine axillary dissection is not recommended. Table 1 Metastatic rates in phyllodes tumours according to grade Table 4 Summary of studies evaluating hormone receptor expression in phyllodes tumours
Study, year Summary of findings
Rao et al., 103 1981 With the dextran charcoal method, tissue samples from five phyllodes tumours and 13 fibroadenomas were analysed for hormone receptors. PR was expressed in five of five phyllodes tumours and in 11 of 13 fibroadenomas. ER was expressed in one of five phyllodes tumours and in two of 13 fibroadenomas. The volumes occupied by epithelium and stroma in each tumour were in keeping with stromal expression of PR and epithelial expression of ER Mechtersheimer et al., 104 1990 Three phyllodes tumours and 13 fibroadenomas studied showed PR and ER expression confined to ductal epithelial cells Singh et al., 105 1996 Sixteen phyllodes tumours (nine benign; seven malignant) studied showed PR expression in all cases (16/16) Twenty-three phyllodes tumour studied showed epithelial c-erb-B2 (HER2) reactivity in 61% of cases; however, no correlation with histological features was found Tse et al., 107 2002
One hundred and forty-three phyllodes tumours studied showed an inverse relationship between epithelial hormonal (ER and PR) expression and tumour grade. Hormonal expression was largely confined to the epithelial component, with ER positivity in 58% of the epithelium and 2.8% of stromal cells, and PR positivity in 74.8% of the epithelium and 1.4% of stromal cells. In the same study, AR expression in both the stromal and epithelial components of phyllodes tumours was low (<5%) across all three tumour grades. Epithelial ER expression showed correlation with stromal mitotic activity, and was predictive of tumour grade A study of 101 patients showed low recurrence rates (actuarial 10-year local failure rates of 7% for benign and borderline tumours, and 9% for malignant tumours, respectively) when local excision with appropriate surgical margins was used as primary treatment of phyllodes tumours, provided that the tumour-to-breast ratio was amenable to good cosmesis A study of 285 cases investigated the benefit of a second excision following initial inadequate (<10 mm) clearance. Tumour size and mitotic activity were found to be independently prognostic of local recurrence, whereas margin status and surgical procedure were not. It was proposed that wide margins, if necessary via re-excision, should be the goal in treating small (<50 mm) tumours with high mitotic activity (>10 mitoses per 10 high-power fields), as these tumours constituted a distinct group associated with a significant (55.6%) local recurrence rate
